Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ginkgo biloba

This article was originally published in The Tan Sheet

Executive Summary

Recruitment underway for four-year Oregon Health Sciences University study examining standardized ginkgo biloba extract's effects in preventing or delaying cognitive decline in people ages 85 and older. Randomized, double-blind trial is enrolling 200 cognitively healthy subjects who will be followed for mild cognitive impairment, a precursor to dementia. Subjects will be randomized to either placebo or 240 mg ginkgo extract per day. Placebo subjects will be placed on ginkgo 24 months after entry. Changes in MRI-determined volume will be assessed at baseline, 24 and 42 months. Principal investigator is Jeffrey Kaye, MD, director of OHSU's Oregon Aging & Alzheimer's Disease Center. OHSU received $7.8 mil. from NCCAM for neurological disorders research in 1999 (1"The Tan Sheet" Oct. 4, 1999, p. 4)

You may also be interested in...

NCCAM Awards Funds For Ginkgo Biloba Trial, Five Research Centers

The National Center for Complementary & Alternative Medicine is sponsoring a multicenter study to test the safety, efficacy and tolerability of ginkgo biloba for the prevention of dementia in the elderly, the center announced Sept. 30.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts